Dyne Therapeutics, Inc. (DYN)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Dyne Therapeutics DYN Annual Report Details Genetic Muscle Disease Therapies Pipeline
Since the actual text of the ARS (Annual Report to Shareholders) for Dyne Therapeutics wasn't included in your message, I'll create a clear, educational breakdown of what this document is and what you would typically find inside it, based on what an ARS contains and public knowledge about Dyne. # �
DYN Proposes Doubling Authorized Shares at Annual Meeting
# 🧾 What This Document Is This is Dyne Therapeutics' **Definitive Proxy Statement (DEF 14A)**. Think of it as the official agenda and background packet for the company's upcoming annual shareholder meeting. It’s sent so shareholders can vote on key company decisions. 👉 **Why it matters:** Your vo
SEC filings
All filings →Insider trades
All insider trades →Dyne Therapeutics, Inc. has no reported insider trades in the last 90 days.